Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “TEVA PHARMACEUTICALS INTERNATIONAL GMBH”

41 pharma patents match "TEVA PHARMACEUTICALS INTERNATIONAL GMBH" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 41
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 41 pharmaceutical patents matching "TEVA PHARMACEUTICALS INTERNATIONAL GMBH" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

41 results for “TEVA PHARMACEUTICALS INTERNATIONAL GMBH” · 30,257 patents in full index Clear search

  1. US 12157729

    Solid state forms of Belumosudil and Belumosudil salts

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  2. US 12139528

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  3. US 12091388

    Solid state forms of Reproxalap

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  4. US 11813359

    Sustained release olanzapine formulations

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  5. US 11773083

    Solid state forms of Belumosudil and Belumosudil salts

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  6. US 11673860

    Crystalline siponimod fumaric acid and polymorphs thereof

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  7. US 11555064

    Treating headache comprising administering an antibody to calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 17, 2023 · Expires Jan 12, 2043

    granted
  8. US 11541177

    Injection spring for aged prefilled syringe and auto injector

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  9. US 11420945

    Solid state forms of Pemafibrate

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  10. US 11306104

    Solid state forms of Relugolix

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  11. US 11220488

    Crystalline polymorph of Ponesimod

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  12. US 11053261

    Solid state forms of ixazomib citrate

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  13. US 11028161

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  14. US 11028160

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  15. US 10899826

    Pharmaceutical compositions for an anti-CGRP antagonist antibody

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted
  16. US 10689352

    Solid state forms of trisodium valsartan: sacubitril

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted
  17. US 10676498

    Processes for the preparation of sofosbuvir and intermediates thereof

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  18. US 10646443

    Sustained release olanzapine formulations

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted May 12, 2020 · Expires May 7, 2040

    granted
  19. US 10604537

    Solid state forms of ixazomib citrate

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Mar 31, 2020 · Expires Mar 26, 2040

    granted
  20. US 10597448

    Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Mar 24, 2020 · Expires Mar 19, 2040

    granted
  21. US 10556945

    Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 11, 2020 · Expires Feb 6, 2040

    granted
  22. US 10519224

    Treating headache comprising administering an antibody to calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted
  23. US 10392434

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  24. US 10329343

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted